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Abstract
Previous studies show that carbohydrate-protein (CP) ingestion can enhance
short-term recovery following exercise, thereby benefiting subsequent exercise
performance

and

compounding

physiological

parameters,

when

compared

to

carbohydrate (CHO) alone. Less is known about the influence that CP supplementation
may have over a long-term intervention (several days/weeks). The purpose of this
investigation was to determine whether CP supplementation was effective in improving
tolerance to a period of intensified training (IT), compared to CHO. Additionally, the
influence of CP on recovery/ adaptation to a period of IT followed by a period of reduced
volume training (RVT) was examined. Eight endurance-trained cyclists (age: 24.9±7.3
years, weight: 71.8±11.5 kg, VO2max: 63.4±7.9 ml/kg/min) completed two independent
training phases, each with a 10 day period of IT, followed by a 10 day period of RVT.
CHO supplementation was provided during (45 g/hr) and immediately following (1.2
g/kgBW) all exercise sessions in one phase, whereas CP treatments was provided
throughout the other phase (45gCHO/hr + 15gPRO/hr during; 1.2gCHO/kgBW +
0.3gPRO/kgBW post). The impact of IT on cycling performance was ‘unclear’ (60 ± 210
sec), with an ‘unclear’ treatment effect. CP ‘likely’ preserved whole muscle function
throughout IT, compared to CHO. Whole muscle size was ‘possibly’ maintained
throughout IT with CP, compared to CHO. While CHO ‘likely’ increased MHC IIa CSA
following IT, CP ‘likely’ increased MHC IIa CSA following RVT, compared to their
respective treatments. Throughout a period of IT, CP supplementation may preserve
whole muscle size and function, compared to CHO. However, CP minimally affected
changes

in

cycling

performance

and

vi

muscle

fiber

size

following

IT.

Chapter One
Introduction
Condensed periods of high volume training combined with minimal rest (i.e.
intensified training - IT) are often incorporated into training cycles of competitive
athletes, with the fundamental goal of improving athletic performance. These training
blocks can temporarily suppress physiological function and lead to short-term
performance decrements (overreaching) (17, 18, 25, 26, 30, 40, 81). Among various other
physiological changes (e.g. progressive decline in muscle glycogen concentration), IT is
associated with declines in skeletal muscle strength and power production (17, 20, 54,
73), reduced muscle fiber size and contractile function (20, 28, 43), increased muscle
soreness (1, 51, 58, 71, 72), and altered markers of muscle damage and physiological
stress including higher creatine kinase (17, 27, 42, 60) and resting cortisol concentration
(42, 74), respectively. These deleterious effects can generally be reversed with as little as
a few days to a week of reduced training (22, 45). Importantly, there is strong evidence
that reduced training (RVT) can enhance performance (compared to pre-taper) across a
range of disciplines, including cycling (40, 52, 55–57), running (34, 35, 68) and
swimming (13, 14, 78). So, IT is commonly followed by a short period of RVT (days) to
minimally foster a return to pre-IT levels of function and to ideally lead to compensatory
adaptive responses that improve performance. One of the chief risks of IT is that normal
short-term decrements in function may persist beyond the period of planned recovery and
consequently necessitate prolonged recovery and/or missed training. Because of the
physical and psychological demands of this training approach, many athletes manipulate

2
their nutritional intake in an attempt to better manage the stresses of IT and to promote
recovery.
The most widespread nutritional strategy used during endurance training is
carbohydrate supplementation. It is widely accepted that depleted muscle glycogen stores
can contribute to fatigue and impaired exercise performance (41). Acute carbohydrate
supplementation is well known to improve endurance performance, which is partially
accomplished by sparing endogenous carbohydrate stores (38). Successive days of IT can
compromise muscle glycogen resynsthesis (5, 15, 16, 69), and consequently impair
performance. Logically, a high carbohydrate diet can result in better maintenance of
exercise performance, compared to a low-carbohydrate diet (1, 26). Moreover, a
carbohydrate-rich dietary strategy (>8 g/kgBW/day) that incorporates optimal timing of
intake (<30 min post-exercise), can sustain muscle glycogen stores and prevent declines
in carbohydrate/glycogen oxidation during periods of heavy training (1, 5, 69, 70).
Carbohydrate supplementation not only helps athletes better tolerate the strains of IT, but
may also enhance the adaptive response. Compared to a low carbohydrate supplement, a
high carbohydrate treatment improved cycling performance from pre-intensified levels
when administered throughout a post-IT taper (26). In addition to highlighting the
potential for nutrition to enhance the benefits of a post-IT taper, these findings support
the vital role carbohydrate intake posses in relation to endurance performance, especially
during a period of IT.
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Short Term Effects of Carbohydrate + Protein: <24 hours
Attention has recently been directed to the potential benefits of adding protein to
carbohydrate feedings during and immediately after exercise. Little has been done to
evaluate the efficacy of protein-enriched CHO supplementation (CP) during IT. Though
the finding is not universal (4, 8, 53, 61, 64), there is plenty of support for short-term
recovery advantages of protein supplementation (<24hrs), meaningful advantages that
translate to improved subsequent performance (2, 3, 19, 49, 66, 80). Worth noting is that
CP feedings can confer ‘next day’ performance benefits even when delivered
isocalorically (replacing a small amount of CHO with PRO) and when following both
primary forms of endurance exercise; running (2, 49) and cycling (3, 19). These data
represent a growing consensus that CP ingestion can enhance recovery from heavy
exercise and subsequent performance. Whether or not these benefits persist throughout IT
is unknown.
Though the gains in performance with CP appear to be at least partially mediated
through skeletal muscle, surprisingly few studies have assessed whole muscle function
(peak force, peak torque) in response to different nutrient intake strategies following
endurance exercise (7, 23, 24, 71, 79) and the results have been mixed. Protein does
appear to have the capacity to better restore whole muscle function after heavy endurance
exercise (24, 71, 79), but this is not evident in all studies (7, 23). The disparate findings
may be a function of the extent of the initial muscle stress and the nuances of the
nutritional intervention.
The documented improvements in performance and muscle function with protein
intake may be related to aspects of muscle damage. Although speculative, CP
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supplementation can potentially reduce muscle damage by maintaining branch chain
amino acid levels in the muscle, resulting in a suppressed signal for proteolysis during
and after prolonged exercise (76). CP ingestion has repeatedly been shown to reduce
post-exercise creatine kinase levels compared to carbohydrate alone (10, 23, 24, 48, 61,
66, 71). In a recent study, CK levels and subsequent performance were measured
following an initial ride to exhaustion to asses the effect of CP during and post-exercise
on muscle damage (66). Subsequent performance was better with the CP treatment (66),
and the authors later reported that the best performances in the subsequent exercise test
occurred in the subjects who received the greatest attenuation of CK after the initial
exercise (12). Post-exercise creatine kinase levels are commonly profiled in conjunction
with perceived muscle soreness to better determine the magnitude of muscle damage.
And similar to the attenuating impact that protein consumption has on creatine kinase,
post-exercise muscle soreness is also typically lower with CP versus CHO alone (24, 48,
53, 61). Collectively, these data suggest that CP supplementation improves acute
recovery from prolonged exercise compared to CHO alone (24).

Intermediate Term Effects of Carbohydrate + Protein: 1-7 days
Given that adding protein to a carbohydrate-treatment has short-term (<24hrs)
benefits, it is logical to speculate that CP supplementation may also improve tolerance
and adaptations to several days or weeks of heavy training. Although not systematically
addressed, initial evidence indicates that protein-rich carbohydrate feedings alleviate the
negative impact that consecutive heavy days of training can have on performance (11, 63,
71). CP supplementation maintained time-to-exhaustion performance during 3
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consecutive days of cycling to fatigue compared to an isocaloric CHO supplement (71).
Additionally, cyclists that consumed CP ad libitum throughout an 8-day mountain bike
race performed better during the final 7 days compared to those that received the CHO
only treatment (11). Lastly, when a protein-enriched diet (CP) was provided over a 4-day
period of high-intensity cycling, recovery from prior exercise bouts was enhanced,
resulting in superior performance on the fourth day compared to a control diet (CHO)
(63). Studies that deviate from this conclusion were not conducted during heavy periods
of training where the beneficial effects of CP ingestion are likely more pronounced (23,
48). Overall, CP intake appears to soften the detrimental effects that heavy cycle training
has on subsequent performance, compared to CHO ingestion alone. As CP ingestion may
sustain exercise performance, whole muscle function, an important feature in endurance
performance, may also be maintained during a period of IT with CP intake compared to
CHO.
Very few studies have investigated the effect of CP supplementation on whole
muscle function during consecutive days of heavy training. During three consecutive
days of cycle training, whole muscle function as assessed by vertical jump height was
better maintained with CP ingestion compared to CHO (71). Similar to the acute model,
the degree of muscle damage may impact the ability to maintain whole muscle function
during a period of IT. Attenuated muscle damage, as indicated by reduced post-exercise
CK levels, has been observed with CP supplementation in cyclists (63, 71), runners (48),
and soccer players (23) during training periods of 3 to 6 days. Additionally, CP intake
evoked a more rapid recovery of post-exercise CK in swimmers during 4-weeks of IT,
compared to CHO alone (10). Similarly, CP ingestion seems to attenuate perception of
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muscle soreness during consecutive days of heavy training compared to CHO (21, 48,
71). Overall, the beneficial effects of CP intake observed in a short-term setting (<24hrs)
seem to translate to longer durations of training.

Prolonged Effects of Carbohydrate + Protein: >7 days
To our knowledge only one prior study has investigated the effects of protein
ingestion within the methodological framework proposed in the current study. Witard and
colleagues recently investigated the efficacy of increased dietary protein (1.5 vs 3.0
gPRO/kgBW/day) on tolerance to a period of intensified training and adaptations during
a week-long reduced volume training phase (81). The high protein diet ‘possibly
attenuated’ performance decrements throughout intensified training, and ‘possibly
enhanced’ performance restoration after a period of reduced-volume training (81).
Importantly, Witard did not assess protein intake within the most nutrient sensitive time
points, during and immediately after exercise. Additionally, the low-protein group
received a fairly large amount of protein (1.5 gPRO/kgBW/day), potentially reducing any
observed difference between treatment groups. Finally, the authors did not profile
changes in skeletal muscle physiology (e.g. whole muscle function, muscle size, and fiber
size). It is well established that periods of IT induce muscle fiber atrophy (20, 28, 43).
And while a period of RVT has independently been shown to permit muscle fibers to
grow (47, 56, 78), no one has assessed whole muscle size or fiber size in individuals
subjected to both training periods. Likewise, the impact that protein ingestion may have
on this response is unknown.
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Therefore, the purpose of this study is to determine if CP supplementation during
and following exercise throughout IT minimizes impairments in subsequent endurance
performance, sustains skeletal muscle size and function, and attenuates markers of
muscle damage, in comparison to CHO supplementation. The study was also designed to
test the hypothesis that CP co-ingestion during and immediately following exercise
during RVT improves subsequent performance, increases whole muscle size and fiber
cross-sectional area, and improves skeletal muscle function, in comparison to CHO
supplementation.
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Aims and Hypotheses
Aim 1:
To determine whether CP ingestion during and following exercise enhances tolerance to
10 days of intensified cycling training in trained cyclists compared to CHO
supplementation.
Hypothesis 1:
CP supplementation during and following exercise throughout intensified training will
better maintain subsequent endurance performance, better sustain skeletal muscle
function and size, attenuate biomarkers of muscle damage, and reduce ratings of
perceived muscle soreness compared to CHO supplementation.

Aim 2:
To determine if CP ingestion during and immediately following exercise enhances
skeletal muscle recovery/adaptations during 10 days of reduced volume training in
trained cyclists compared to CHO supplementation.
Hypothesis 2:
CP ingestion during and immediately following exercise throughout a period of reduced
volume training will facilitate larger improvements in subsequent performance, larger
improvements in skeletal muscle function, and larger increases in whole muscle size and
muscle fiber cross-sectional area compared to CHO supplementation alone.
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Significance
There is a variety of evidence that CP ingestion can enhance short-term recovery
following exercise, thereby benefiting subsequent exercise performance, when compared
to CHO alone (3, 19, 49, 66, 80). Skeletal muscle function is also improved with CP
intake (24, 66, 71, 79); possibly due to attenuations in muscle damage indicated by
reduced post-exercise CK levels (10, 23, 24, 48, 61, 66, 71) and ratings of muscle
soreness (24, 48, 53, 61).
Less is known about the influence that CP supplementation may have over a longterm intervention (several days/weeks). There are a few studies indicating CP ingestion
may enhance subsequent exercise performance during periods of heavy endurance
training ranging from 3 to 10 days compared to CHO alone (11, 63, 71, 81). Accordingly,
skeletal muscle function may be maintained (71), while post-exercise CK levels (10, 23,
48, 71) and ratings of muscle soreness (21, 71) are attenuated with CP supplement.
Moreover, these markers of improved recovery may occur as a consequence of the ability
of CP to expedite post-exercise glycogen resynthesis (4, 39) and enhance protein balance
during (37, 44) and following (9, 29, 36, 37, 49) endurance exercise. Surprisingly, little is
known about the effects of during-or post-exercise nutrition on whole-muscle and fiber
size. To date, no one has examined the effect of CP supplementation during and
immediately after exercise on tolerance and subsequent recovery/ adaptation to a period
of IT followed by a period of RT. The results of this study, together with the
comprehensive findings on the effects of supplemental protein in an acute setting, would
provide insight into the potential that CP may possess in better supporting athletes
undergoing periods of IT.
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Chapter Two
Methods

SUBJECTS
Eight to twelve, male and female, endurance-trained cyclists between the ages of
18 and 45 years will be recruited from local cycling clubs, including the James Madison
University Triathlon and Cycling Club teams. To be included, subjects must possess a
VO2max ≥ 50ml/kg/min or 4.0 L/min. Additionally, all subjects will have completed ≥ 7 hr
of cycle training each week for 2 months preceding participation. Study procedures have
been approved by the James Madison University Institutional Review Board. Before
participation, and after comprehensive verbal and written explanations of the study, all
subjects will provide written, informed consent.

EXPERIMENTAL DESIGN
Subjects will perform two separate training blocks separated by a ≥ 2-wk washout
period (Figure 2.1). Each training block consists of distinct periods of normal training
(NT), intensified cycle training (IT), and reduced-volume training (RVT), as described
below. During each separate training block, subjects will receive one of two potential
nutritional interventions. The two nutritional interventions incorporate feedings of either
a carbohydrate (CHO) or protein-enriched carbohydrate (CP) supplement during and
post-exercise. A crossover design will be utilized such that each subject receives both
nutrition interventions, with order of nutritional treatment randomly counterbalanced
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among subjects. Subjects that meet the inclusion criteria will be familiarized with all
testing procedures during the second week of NT.
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Figure 2.1. Experimental Design
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Training Quantification
Normal Training (NT)
Prior to any intervention, subjects will be instructed to perform their customary
training habits for two weeks. The first week of NT will be used to quantify normal
training volumes. The second week of normal training will be used for familiarization
trials of all performance tests prior to nutritional intervention. Cycling during
familiarization trials will be factored into the subject’s normal weekly training volume.
Training details gathered during NT will be used to prescribe training volumes and
intensities throughout the investigation. Each subject will be provided with a rear bicycle
wheel equipped with an integrated PowerTap system (Saris Cycling Group Inc, Madison
WI). These units are used to quantify power output, heart rate, total exercise duration and
distance during all training sessions conducted outside the laboratory. Cycling power
output and training heart rate will be used as indices of training intensity, whereas total
training duration (minutes) will be used to quantify training volume.

Intensified Cycle Training (IT)
Immediately following NT, subjects will perform 10 days of IT, consisting of a
100% increase in average daily training volume. Cycling performance tests (preloaded
Time Trial) will be conducted on days 1, 4, 7, and 10 and will contribute to total training
load during IT (Figure 2.2). Training on days 2, 3, 5, 6, 8, and 9 will be executed outside
of the laboratory. Subjects will be provided with individualized training guidelines for
these days based on their training volume during NT. Power Tap units will be utilized
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during all training days, and power output, heart rate, and training duration will be
recorded to verify compliance to the training guidelines.

Reduced Volume Training (RVT)
Immediately following IT, subjects will perform 10 days of RVT in which
average daily training volume is reduced by 60% relative to NT. A cycling performance
test will be conducted on day 10 and will contribute to total training load during RVT
(Figure 2.2). Similar to above, power output, heart rate, and training duration will be
recorded during all sessions.

Washout (WO)
A washout phase of ≥ 2 weeks will follow RVT. WO will be comprised of an
individualized initial period of recovery, with the intent of restoring normal training loads
by the end of the washout period. Following the washout period, subjects will participate
in one week of NT (replicating training habits from the first NT period), before initiating
a

second

phase

of

IT

and

RVT

training.
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Figure 2.2. Study Schematic with Corresponding Data Collection

Intensified Cycling Training
Days

-3

VO2max

-1

1

2

3

4

5

6

7

X

TT
Bx

-2

9

10

1

X
X

X

8

Reduced Volume Training

X

X

2

3

4

5

6

7

8

9

10

+1

X
X

X
X

X

VO2max = VO2max, TT = preloaded time trial, Bx = skeletal muscle biopsy
Note: This design will be repeated twice (Figure 1). Therefore, days -1, -2, and -3 correspond to the final 3 days of normal
training, whereas day +1 corresponds to day 1 of washout or study completion.
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NUTRITIONAL TREATMENTS AND DIETARY CONTROLS
Treatment beverages will be administered during and immediately following all
training sessions throughout IT and RVT (20 total CHO sessions and 20 CP sessions).
During all laboratory TT sessions (Figure 2.2), subjects will ingest 250 ml of fluid every
20 minutes until TT completion (750 ml·hr-1; details provided below). For all rides
performed in the field (IT 2, 3, 5, 6, 8, 9 and RVT days 2-9), participants will be provided
with 500 ml bottles filled with the appropriate beverage, and instructed to ingest 1 bottle
during each 40-minute block of training (750 ml·hr-1). Following each ride, participants
will be supplied with bottles containing an individualized volume of fluid and instructed
to finish the beverage within 30 minutes of terminating exercise. Participants will be
instructed to avoid any other beverage or food intake for 2 hrs following the completion
of each exercise session, with the exception of ad libitum water consumption.
Additionally, subjects will be instructed to record any volume of unfinished post-exercise
beverages.

During Exercise
CP
The during-exercise CP treatment will be Gatorade® with additional hydrolyzed
whey protein isolate, obtained from American Casein Company (AMCO, Burlington NJ).
During all training sessions, beverages (6% carbohydrate, 2% protein) will be ingested at
a rate of 750 ml·hr-1, which provides subjects with 45 g CHO·hr -1 and 15 g PRO·hr -1.
#
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CHO
The during-exercise CHO treatment will be Gatorade® (without additional
protein). During all training sessions, beverages (6% carbohydrate) will be ingested at a
rate of 45 g CHO·hr

-1

(750 ml of fluid·hr -1), providing equal carbohydrate content to

CP, and a similar flavor of either lemon-lime or fruit-punch.

Post-Exercise
CP
Immediately following each training session, a non-fat chocolate milk beverage
will be provided. Each serving consists of 9.93 ml·kg BW-1, and provides 1.2 g CHO·kg
BW-1 and 0.4 g PRO·kg BW-1.

CHO
Immediately following each training session, an isocarbohydrate beverage,
relative to CP, will be provided. Each serving consists of 9.93 ml·kg BW-1, and provides
1.2 g CHO·kg BW-1. The beverage will be created by mixing the appropriate amount of
commercially available chocolate flavored carbohydrate gels (Clif Shots) with water,
providing a similar taste/color compared to non-fat chocolate milk.

Dietary Controls
During the time period between the onset of each training session and 2 hrs
following each training session, participants will not receive any nutrients other than the
CHO or CP beverages. Prior to any nutritional intervention, subjects will complete a
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nutritional consultation with a registered dietician to review acceptable dietary choices
during training periods and instructions on completing dietary records. 24-hour dietary
records will be gathered during NT, whereupon individualized feedback will be provided
about total caloric- and macronutrient intake; participants with inadequate daily
carbohydrate intake (<6.5 g·kgBW-1·day-1) will be encouraged to increase their dietary
carbohydrate levels prior to the training intervention. Dietary intake will also be recorded
throughout IT (10 days) and RVT (10 days). Using copies of dietary records obtained
from the first intervention phase, subjects will then be instructed to replicate their dietary
habits during the second phase of the cross-over design. Subjects will submit their dietary
intake forms every three days during the IT and RVT periods. During the second phase,
subjects will be provided with forms listing their exact diet from the first phase, as well
as two possible substitutions for each corresponding meal. Researchers will contact the
subjects with specific dietary suggestions if dietary intake intakes vary appreciably from
the prescribed dietary guidelines.
All laboratory testing (i.e. skeletal muscle biopsies, VO2max tests, and TT) will be
performed after an 8-10 hr overnight fast (ad libitum water consumption). In addition,
subjects will be provided with a standardized boxed-lunch at all laboratory sessions. The
standardized boxed-lunch will include two sandwiches from a selected menu, a bag of
potato chips, and a beverage of choice. Subjects will be provided with several choices of
lunch contents, provided by JMU dining services (ARAMARK) and are required to
repeat the selection throughout the duration of the study (phase 1 and phase 2). Subjects
will be instructed to consume all contents of the boxed-lunch and to record all
unconsumed boxed-lunch contents during the 2-6 hr post-exercise period with only ad
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libitum water consumption permitted during this time period. Subjects will be provided
with several choices of lunch contents, provided by JMU dining services (ARAMARK)
and are required to repeat the selection throughout the duration of the study (phase 1 and
phase 2). This will allow for the standardization of dietary intake for approximately 6
hours after each laboratory time trial session.

MEASUREMENTS
Endurance Performance
VO2max test
Subjects that meet the inclusion criteria will complete an incremental exercise test
to determine VO2max. Height and weight will be recorded prior to the incremental exercise
test, which will take place prior to the initial phase of NT. The test will be conducted on a
computerized cycle ergometer (Velotron, Racermate Inc, Seattle WA). Subjects will
warm-up for 5 mins at an individualized workload based on a light perceived exertion.
The workload will be increased by 25 W every 2 min until subjects voluntarily request to
stop due to fatigue or are unable to maintain a cadence of >50 rpm. Oxygen uptake will
be assessed during each stage in 30-s intervals using indirect calorimetry via an
automated Moxus Modular Metabolic System (AEI Technologies, Bostrop TX) and
SensorMedics VMax 229 metabolic cart (Yorba Linda, CA). The initial VO2max test will
be used for inclusion/exclusion, and as a familiarization for subsequent VO2max testing.
Test duration (time to fatigue) will be used as a measure of performance.
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Preloaded Time-trial (TT)
Subjects will perform TT’s on a computerized cycle ergometer (Velotron,
Racermate Inc, Seattle WA) on IT days 1, 4, 7, 10 and RVT day 10, as illustrated in
Figure 2.2. The TT will include an initial period of 120 minutes of cycling at 50% Wmax
(obtained from VO2max test) followed immediately by a simulated 30-km time trial. 30km TT finishing times and average power output will be recorded and used as
performance measures. Each TT will contribute to the training load during IT and RVT,
and therefore the same nutritional guidelines as field training sessions will be utilized.

Skeletal Muscle Physiology
Peak Isokinetic Force (Bdx)
Peak isokinetic concentric muscle force will be assessed following a standardized
5-min warm-up on a cycle ergometer. This test will be conducted using a Biodex
isokinetic dynamometer (Biodex Medical System Inc., Shirley NY). Peak unilateral
isokinetic force (power) will be assessed by having subjects push as hard as possible
against a shin pad connected to an electronic device that controls the speed of movement
through the leg-extension. Subjects will perform a maximal effort on four occasions for
each speed, with each repetition separated by 30s of rest. Selected rotational speeds are
240 degrees/sec and 120 degrees/second. The faster speed will be performed first in order
to avoid premature muscular fatigue before conducting the later speed. This assessment
will be performed immediately following each skeletal muscle biopsy (using the non
biopsied leg).
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Maximal Voluntary Contraction (MVC)
Skeletal muscle function will be assessed immediately before each VO2max test
using a custom-built leg extension device to determine peak unilateral isometric
contraction force. Following a standardized 5-min warm-up (3mph treadmill walk),
subjects will be positioned in the leg extension device and prompted to exert maximum
force against a shin bar for three seconds on four occasions, with each repetition
separated by 1min of rest. Peak force will be recorded in Newtons, using the right leg.

Serum Creatine Kinase (CK) and Cortisol
Fasting venous blood samples will be obtained from an antecubital vein prior to
TT1, TT4, TT5 and following the 2-hr fixed intensity phase of the TT protocol (6 total).
Upon entering the lab, subjects will rest in an upright phlebotomy cathedra for 5 min
prior to receiving blood draw. Following the 2-hr fixed intensity phase of the TT
protocol, subjects will be instructed to return to the phlebotomy cathedra from the cycle
ergometer as quickly as possible to receive their second blood draw. Transition time
from cycle ergometer to initiation of blood draw will be recorded and standardized for
subsequent trials. Approximately 10 ml of whole blood will be obtained at each blood
draw and centrifuged at 10000 rpm following 30 min of coagulation. Serum samples will
be stored at -80o for later analysis. CK will be subsequently analyzed using an automated
table-top analyzer (Johnson and Johnson Vitro DT 6011), whereas cortisol will be
analyzed using standard enzyme-linked immunosorbent assay (ELISA) procedures. CK
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and cortisol levels will be measured to indicate levels of cellular membrane damage and
inflammation respectively.

Muscle Soreness
Soreness ratings will be obtained prior to each lab visit (VO2max, TT, Biopsy)
using a 100mm visual analog scale, with 0 indicating no muscle soreness and 100
indicating impaired movement due to muscle soreness.

Skeletal Muscle Size
Vastus Lateralis (VL) thickness will be measured using a Shenzen Mindray DC-6
ultrasound device (Nanshan, Shenzen, China) in B-mode with a 10MHz capacity linear
array transducer. During the initial visit, mid-muscle belly of the VL will be identified
and recorded for subsequent visits, using a technique adapted from Kumagai et al. (46).
The distance between the bony protuberance of the greater trochanter of the femur to the
prominence of the lateral femoral condyle will be determined. This point will then be
intersected with a perpendicular line drawn from the midway point through a vertical line
drawn from the lateral border of the patella past the midway point of the greater
trochanter and femoral condyle. This point is where the ultrasound images will be
captured. Subjects will be positioned sitting upright, using a custom-built device to
standardize the selected leg position. Subject will rest in this position for 15min prior to
obtaining the ultrasound measurement. Using the 7.5MHz probe frequency setting, the
transducer head will be positioned until the aponeuroses of the VL can be clearly
delineated. Upon capturing images, the outline of the transducer head will be outlined
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with a surgical skin marker denoting the location for future imaging. Further, the subjects
will be provided with personal skin markers and instructed to maintain the initial marking
until the subsequent trial. This measurement will be made prior to each VO2max test.

Muscle Fiber Size
Skeletal Muscle Biopsies
Vastus Lateralis (VL) muscle biopsies will be obtained on the dates indicated in
Figure 2.2 (6 total). At each time point, percutaneous needle biopsies will be obtained
under local anesthetic (2-3 ml Lidocaine) (6). Muscle samples will be dissected free of
any visible connective and adipose tissue and frozen in isopentane, cooled in a liquid
nitrogen bath. Samples will be stored at -80oC for later analysis.
Immunohistochemistry
Serial cross-sections (5 um) will be cut at -25oC (Minotome Plus; Triangle
Biomedical Sciences, Durham, NC) from biopsy samples and will be arranged on an
uncoated glass slide. The details of the combined stain of glycogen (PAS) with
immunofluorescence are summarized in Table 2.1. Sections will be fixed for 1 h at 4oC
with 3.7% formaldehyde (Fisher Scientific, Fair Lawn, NJ) in PBS immediately after
removal from the freezer. Next, the slides will be rinsed for 10 min in PBS and treated
with 0.1% Triton X-100 (Acros Organics, Geel, Germany) for 5 minutes. After the
fixation and permeability steps, the PAS staining will be begin by rinsing the slides in
PBS for 15 min and deionized water (D.I. H2O) for 30 s. Then slides will be treated with
1% periodic acid (Sigma-Aldrich, St. Louis, MO) in D.I. H2O followed by a wash in D.I.
H2O for 1 min. Slides will then undergo incubation in Schiff’s reagent (Sigma-Aldirch,
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St. Louis, MO) for 15 min at room temperature followed by washing steps in D.I. H2O
for 5 s and running tap water for 10 min. Thereafter, slides will be rinsed with PBS for
15 min and incubated for 30 min with blocking buffer (0.05% Triton X-100, Normal
Goat Serum). Different concentrations of primary antibodies in 0.05% Triton X-100 will
be applied to the slides for 2 h at room temperature. Slides will be rinsed for 30 min with
0.05% Triton X-100 in PBS and incubated with appropriate conjugated secondary
antibodies for 2 h at room temperature, in the dark. After incubation, the slides will be
rinsed in the dark for 30 min with 0.05% Triton X-100 in PBS. After a final rinse in the
dark for 15 min in PBS, coverslips will be mounted on the slides with Fluormount G
mounting medium (Southern Biotechnology Associates, Birmingham, AL) and stored in
the dark at 4oC for later analysis.
Primary and Secondary Antibodies
Muscle fiber type and cross-sectional area will be assessed through application of
the following monoclonal primary antibodies: A4.840 supernatant, a mouse monoclonal
IgM antibody directed against human myosin heavy chain I (MHC I) (Developmental
Studies Hybridoma Bank, Iowa City, Iowa); SC-71, supernatant, a mouse monoclonal
IgG1 antibody directed against human myosin heavy chain IIa (MHC IIa)
(Developmental Studies Hybridoma Bank, Iowa City, Iowa); and 2E8 supernatant, a
mouse monoclonal IgG2a antibody directed at human laminin, a basement membrane
protein (Developmental Studies Hybridoma Bank, Iowa City, Iowa).

Each primary

antibody will be paired with its appropriate conjugated secondary antibodies: MHC I,
Alexa Fluor 555 Goat anti-mouse IgM; MHC IIa, MHCIIa: Alexa Fluor 647 Goat anti-
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mouse IgG1; Laminin, Alexa Fluor 488 Goat anti-mouse IgG2a (Molecular Probes,
Leiden, The Netherlands).
Imaging and Quantification
Slides will be examined using fluorescent microscopy (Nikon Eclipse TE2000-E,
Tokyo Japan). Within each sample, the largest possible area will be imaged.
Epifluorescence signal will be recorded using Texas Red excitation filter (534-556 nm)
and Cy5 excitation filter (628-672 nm) for MHCI and MHCIIa muscle fibers,
respectively. Additionally, FITC excitation filter (450-490 nm) will be used to record
epifluorescence signal for laminin. Images will be captured in each filter and overlaid
using NIS Elements software (Nikon, Tokyo, Japan). Cross-sectional area will be
determined by measuring the laminin-positive stain outlining each muscle fiber;
peripheral muscle fibers that have irregular edge staining patterns or disrupted cell
membranes will be marked and excluded from analyses. This quantification will provide
a fiber-type specific measure of cross-sectional area.
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Table 2.1. Staining Protocol for periodic acid-Schiff (PAS) staining with
immunofluorescence (IF)
Treatment
PAS with IF
Fixation
3.7% Formaldehyde in PBS for 60min @ 4oC
Rinsing
PBS for 10min (2 x 5min)
Permeabilisation
0.1% Triton X-100 in PBS for 5min
Rinsing
PBS for 15min (3 x 5min)
Rinsing
Deionized (D.I.) H2O for 30sec
Pretreatment
1% Periodic acid in D.I. H2O for 5min
Rinsing
D.I. H2O for 1 min
Staining
Schiff’s Reagent for 15min @ room temp.
Rinsing
D.I. H2O for 5sec and tap water for 10min
Rinsing
PBS for 15min (3 x 5min)
Incubation
10% NGS in 0.05% Triton X-100 for 30min @ room temp.
Incubation
Primary antibodies in 0.05% Triton X-100 for 2hr @ room temp.
Rinsing
0.05% Triton X-100 in PBS for 30min (5 x 6min)
Secondary antibodies in 0.05% Triton X-100 for 2hr @ room temp.
Incubation
(in dark)
Rinsing
0.05% Triton X-100 in PBS for 30min (5 x 6min) (in dark)
Rinsing
PBS for 15min (3 x 5min) (in dark)
Mounting
Fluormount G (in dark)
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STATISTICAL ANALYSIS
All data will be log transformed to diminish the effects of nonuniformity. For
each measurement variable, change scores between the three measurement time points,
within each treatment, will be calculated. Dependent T-tests comparing the change scores
between treatments will be applied to generate p-values for subsequent analysis, as
described below. Statistical analyses will be performed using IBM Statistical Package for
Social Sciences (SPSS) 21 for Macintosh (SPSS Inc., Chicago, IL, USA).
Magnitude-based inferences about the data will be derived using methods
described by Hopkins and colleagues (31). A standardized difference in means (mean
difference between treatments divided by the between-subject SD under CHO conditions:
SD units) will be calculated for each variable whereby observed values equivalent to or
exceeding 0.2 SD units will qualify as a substantial treatment effect (i.e. threshold for
substantial effect) (31). The 0.2 SD unit threshold is used for all variables with the
exception of time trial performance, for which a previously established ‘smallest
worthwhile change’ in performance is used as the threshold (32). The smallest
worthwhile change in performance has been defined as 0.3 x the within subject variability
across repeated time trials, which translates to a ~1% change in performance (0.3 x
3.4%), 0.13 SD units, or ~35 seconds for the current data (32).
A published spreadsheet (33) will be used to determine the likelihoods of the true
treatment effect (of the population) reaching the substantial change threshold (0.2 SD);
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% =
unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = almost
certain. If the percent chance of the effect reaching the substantial change threshold is
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<25% and the effect was clear, it is classified as a ‘trivial’ effect. If 90% confidence
intervals included values that exceeded the substantial change threshold for both a
positive and negative effect, effects will be classified as ‘unclear’ (>5% chance of
reaching the substantial threshold for both a positive and negative effect). For ease of
interpretation data will be displayed as raw means ± SD and/or percent difference
between treatments ± CL (90% confidence limit; to illustrate uncertainty in treatment
effects).
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Introduction
Condensed periods of high volume training with minimal rest (i.e. intensified
training, IT) are often incorporated into the training cycles of competitive athletes, with a
fundamental goal of improving athletic performance. These training blocks can suppress
physiological function, leading to short-term performance decrements (17, 18, 25, 27, 30,
40, 81) and various other physiological changes that include declines in skeletal muscle
strength/power (17, 20, 54, 73), and reduced muscle fiber size and contractile function
(20, 28, 43). Periods of IT are generally followed by a short period (i.e. several days) of
reduced volume training (RVT). This strategy is widely observed to promote a return to
pre-IT levels of function and often lead to compensatory adaptations, thus improving
performance (13, 34, 40, 45). Many athletes also manipulate their nutritional intake
during heavy training in an attempt to better manage the stresses of IT, and improve
recovery.
Carbohydrate (CHO) supplementation is the most widespread nutritional strategy
used during endurance training and has demonstrated the ability to maintain exercise
performance during heavy training, potentially via preserved muscle glycogen stores and
sustained carbohydrate oxidation rates during periods of IT (1, 5, 26). In addition to
helping athletes better tolerate the strains of IT, CHO may also enhance the adaptive
response throughout a period of RVT (26). While CHO has been widely shown to be
effective, little has been done to evaluate the efficacy of protein-enriched CHO (CP)
supplementation during IT.
The effects of acute (<24hrs) CP supplementation during and immediately after
exercise have received considerable attention over the past decade. Though the finding is
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not universal (8, 61, 64), CP feedings can translate to improved subsequent performance
(19, 49, 65, 66) versus CHO alone, even when delivered isocalorically (19, 49). The gains
in performance with CP appear to be partially mediated through skeletal muscle, where
whole muscle function (strength/power), an important component in endurance
performance, appears to be restored after IT when CP is administered (24, 71, 79).
Further, these documented improvements in performance and muscle function with CP
may result from the attenuation of muscle damage. CP can potentially reduce signs of
muscle damage, compared to CHO (10, 23, 48, 61, 66). Given that adding protein to a
carbohydrate-beverage has short-term benefits, it is logical to speculate its effectiveness
during longer blocks of heavy training.
Overall, the existing body of literature appears to demonstrate that CP ingestion
attenuates the detrimental effects of heavy endurance training on subsequent performance
(11, 63, 71). Although relatively few multi-day studies have been completed, CP
supplementation seems to better preserve whole muscle function (71) and attenuate
muscle damage compared to CHO (21, 48, 63, 71). A recent study (81) reported
increased dietary protein (1.5 vs. 3.0 gPRO/kgBW/day) to ‘possibly attenuate’
performance decrements during one week of IT, and ‘possibly enhance’ performance
restoration after one week of RVT (81). However, this study did not examine changes in
skeletal muscle physiology (i.e. whole muscle function, muscle size, and fiber size), nor
has anyone assessed whole muscle or fiber size in individuals subjected to both IT and
RVT.
The purpose of this study was to examine the effect of protein-enriched
carbohydrate supplementation on tolerance to 10 days of IT and subsequent adaptation
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following 10 days of RVT. We hypothesized that 1) CP supplementation throughout IT
would minimize impairments in performance, sustain skeletal muscle size and function,
and attenuate markers of muscle damage compared to CHO and 2) CP ingestion
throughout RVT would improve subsequent performance, increase whole muscle size
and fiber size, and improve muscle function compared to CHO alone.
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MATERIALS AND METHOD
Subjects
Ten male (n=8) and female (n=2) endurance-trained cyclists from James Madison
University and the Harrisonburg, VA area were recruited to participate in this study. One
subject was excluded due to noncompliance to standardization procedures, while another
withdrew due to circumstances unrelated to the study, resulting in a total of 8 subjects (6
males; 2 females). Intervention timing was standardized relative to the menstrual phase of
both female subjects. Subjects were required to have competed ≥ 7 hrs of weekly cycling
for two months prior to participation in the study. Subjects were provided written and
oral information about experimental procedures and potential risks prior to giving
informed consent. All procedures were approved by the James Madison University
Institutional Review Board prior to testing. Subject characteristics are displayed in Table
3.1.

Experimental Design
Subjects completed two separate training blocks, each consisting of three distinct
periods of training: Normal training (NT), intensified cycle training (IT), and reducedvolume training (RVT) (Figure 2.1). A double blind, partially counterbalanced, crossover
design was implemented whereby subjects received one of two potential nutritional
interventions during IT and RVT of each training block. The nutritional interventions
were during- and post-exercise feeding of either carbohydrate (CHO) or protein-enriched
carbohydrate (CP) supplement. Training blocks were separated by ≥ 2-wk washout
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period. Subjects were familiarized with all testing procedures during the second week of
NT during the initial training block.

Training Procedures
Training quantification
In order to monitor training as accurately as possible and standardize training
stimuli between phases, subjects were provided with a rear bicycle wheel equipped with
an integrated PowerTap system (Saris Cycling Group Inc, Madison WI). Power output,
heart rate, exercise duration, and distance were recorded during all training sessions
outside of the laboratory.
Training details gathered in the first week of NT, at the onset of the study, were
used to prescribe training duration and power output throughout the investigation. All
familiarization trials were performed during the second week of NT. Immediately
following NT, subjects performed 10 days of IT, which consisted of a 100% increase in
average daily training volume, relative to the first week of NT. Based on the training
volume during NT, individualized training guidelines, incorporating all experimental
testing, were provided to the subjects for IT and RVT. During IT, subjects cycled daily,
performing preloaded time trials (detailed below) on IT days 1, 4, 7, and 10, which
contributed to total training load. During RVT, average daily training volume was
reduced by 60% relative to NT. A cycling time trial was performed on day 10 and
contributed to total training load (Figure 2.2). Each training block was separated by a
washout phase of ≥ 2 weeks following RVT. The washout phase allowed subjects as
much time as needed to fully recover from phase one. Upon full recovery, subjects
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progressed training to then replicate the second week of NT from phase one prior to
initiating the second training phase. Training details were replicated from one training
phase to the next.

Nutritional Treatments and Dietary Control
Prior to any nutritional intervention, subjects completed a nutritional consultation
with a registered dietician to overview acceptable dietary choices and instruction on
completing dietary records. Twenty-four hr dietary records were gathered during the last
two days of NT and everyday throughout IT and RVT. Subjects were provided with
copies of their dietary records from the first phase and instructed to replicate dietary
habits during the second intervention phase. Caloric and macronutrient intake were
similar between the interventions (Table 3.3).
All laboratory testing was performed after an 8-10 hr overnight fast. Additionally,
subjects were provided with a standardized boxed-lunch, prepared by JMU dining
services (ARAMARK), following all laboratory sessions. Treatment beverages were
administered during and following all training sessions throughout IT and RVT. During
all training sessions, subjects ingested either a CHO or CP supplement at a rate of 750
ml·hr-1. Immediately following each training session, subjects consumed an
individualized amount (9.93 ml·kg BW-1) of either a CHO or CP supplement (Table 3.2).
In an attempt to better control nutritional intake in close proximity to exercise, subjects
abstained from any other caloric intake for 2 hrs following the completion of each
training session.

43

Experimental Trials
VO2max test
Subjects

performed

an

incremental

exercise

test

to

fatigue

on

an

electromagnetically braked cycle ergometer (Velotron, Racermate Inc, Seattle WA) to
determine Wmax, and VO2max, as previously described (67). Following a standardized 5
min warm-up, subjects began the test at a self-selected workload estimated as “a
moderate pace for a 60 min ride.” Power was increased by 25 W every two min until the
subject reached volitional exhaustion. Metabolic measurements were assessed throughout
the test using a Moxus Modular Metabolic System (AEI Technologies, Bostrop TX) and
SensorMedics VMax 229 metabolic cart (Yorba Linda, CA). VO2max was determined by
the highest 30 sec mean oxygen uptake value. Wmax was defined by the power
corresponding to the final successful stage, and was used to prescribe workload for the
120 min constant-load period of the subsequent time trials. Prior to NT, a preliminary
VO2max was performed to confirm inclusion criteria was met, and also serve as a
familiarization to testing procedures. Three VO2max tests were performed during each
training phase (Figure 2.2).

Time trial (TT)
Subjects performed five preloaded time-trials on IT days 1, 4, 7, 10, and RVT day
10, as illustrated in Figure 2.2. Additionally, a familiarization time trial was performed
during the 7 days prior to IT to acquaint subjects with testing procedures. The TT
consisted of 120 min of constant-load cycling at 50% Wmax (164 W ± 29 W) followed
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immediately by a simulated 30-km TT, as previously described (67). A pedestal fan was
placed ~2 m from the handlebars and utilized on high speed setting to provide uniform
cooling during each trial. Transition time from the constant-load cycling period to the
simulated 30-km was standardized for all trials. Subjects were instructed to treat the 30km portion of each trial as a competition and provide a maximal effort. No feedback was
provided during the 30-km other than elapsed distance.

Peak isokinetic force (Bdx)
Peak isokinetic concentric muscle force of the knee flexors and extensors was
assessed using a Biodex isokinetic dynamometer (Biodex Medical System Inc., Shirley
NY) following a standardized 5 min warm-up. Two rotational speeds were used for
testing, 240 degrees·sec-1 and 120 degrees·sec-1. Four trials, of one maximal repetition
each, were performed at each speed, with each trial separated by 30 sec of rest. Testing
was performed immediately following each skeletal muscle biopsy, using the nonbiopsied leg. Within a training phase, biopsies were performed on the same leg, with the
contralateral leg biopsied during the opposite phase. Furthermore, opposite legs were
used for peak force assessments between training phases.

Maximal voluntary contraction (MVC)
Peak unilateral isometric force of the knee extensors was assessed using a custombuilt leg extension device. Following a standardized 5 min warm-up subjects provided a
maximal contraction against a stationary shin bar for 3 sec on four occasions, with each
repetition separated by 1 min of rest.
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Blood analysis
Fasting venous blood samples were obtained from an antecubital vein before TT1,
TT4, and TT5. Upon entering the lab, subjects rested in an seated position for 5 min.
Approximately 4 ml of whole blood was then obtained [5 ml BD Vacutainer Serum
Separation (SST) tube with Polymer gel, Silica activator (Becton Dickinson & Company,
Franklin Lakes, NJ, USA)] and centrifuged at 3000 rpm for 10 min at 4oC following 30
min of coagulation. Serum was extracted and stored at -80o C for later analysis. Plasma
CK was analyzed using an automated biochemical assay instrument (ChemWell-T 4600,
Awareness Technolgoy Inc., Palm City, FL). Cortisol was analyzed using quantikine high
sensitivity enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN,
USA).

Muscle soreness
Soreness rating were obtained prior to each lab visit using a 100 mm visual analog
scale, with 0 indicating no muscle soreness and 100 indicating extreme soreness.

Skeletal muscle size
Vastus Lateralis (VL) thickness was measured using a Shenzen Mindray DC-6
ultrasound device (Nanshan, Shenzen, China) in B-mode with a 10MHz capacity linear
array transducer. During the initial visit, mid-muscle belly of the VL was identified and
recorded for subsequent visits, using a technique adapted from Kumagi et al. (46).
Subjects were positioned sitting upright, using a custom-built device to standardize leg
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position, where they rested for 15 min prior to obtaining ultrasound measurement.
Ultrasound imaging was performed using the 7.5MHz probe frequency at the
aforementioned site on the VL. Probe position relative to the VL was recorded for
subsequent measurements using a surgical skin marker.

Skeletal muscle biopsies (Bx)
A total of six muscle biopsies were collected from the VL (6) (3 from each leg),
as indicated in Figure 2.2. Muscle samples were quickly dissected free of any visible
connective tissue and adipose tissue, frozen in liquid nitrogen-cooled isopentane, and
stores at -80oC for later analysis.

Immunohistochemistry
Serial cross-sections (5 um) were cut at -25oC (Minotome Plus; Triangle
Biomedical Sciences, Durham, NC) and arranged on an uncoated glass slide. Details of
the combined stain glycogen (PAS) with immunofluorescence are summarized in Table
2.1. Following fixation in 3.7% formaldehyde (Fisher Scientific, Fair Lawn, NJ) for
60min at 4oC, sections were rinsed in PBS for 10 min and treated with 0.1% Triton X-100
(Acros Organics, Geel, Germany) for 5 min. After fixation and permeabilisation, PAS
staining was performed by treating sections with 1% periodic acid (Sigma-Aldrich, St.
Louis, MO) followed by a wash in D.I. H2O for 1 min. Sections were then incubated in
Schiff’s reagent (Sigma-Aldrich, St. Louis, MO) for 15 min, followed by washing steps
in D.I. H2O for 5 sec and running tap water for 10 min. Thereafter, slides were rinsed in
PBS for 15 min and incubated in blocking buffer (10% Normal Goat Serum in 0.05%
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Triton X-100). Sections were incubated in primary antibodies for 1 hr at room
temperature, rinsed for 30 minutes in 0.05% Triton X-100, and treated with appropriate
secondary antibodies for 1 hr at room temperature, in the dark. After a final 30 min rinse
in 0.05% Triton X-100 and 15 min rinse in PBS, coverslips were mounted on slides with
Fluormount G mounting medium (Southern Biotechnology Associates, Birmingham, AL)
and stored in the dark at 4oC for later analysis.

Primary and secondary antibodies
Fiber type and cross-sectional area are shown through application of the following
monoclonal primary antibodies (Developmental Studies Hybridoma Bank, Iowa City,
IA): A4.840 supernatant, a mouse monoclonal IgM antibody directed against human
myosin heavy chain I (MHC I); SC-71 supernatant, a mouse monoclonal IgG1 antibody
directed against human myosin heavy chain IIa (MHC IIa); and 2E8 supernatant, a mouse
monoclonal IgG2a antibody directed at human laminin, a basement membrane protein.
Each primary antibody was paired with an appropriate conjugated secondary antibody
(Molecular Probes, Leiden, The Netherlands): MHC I, Alexa Fluor 555 Goat anti-mouse
IgM; MHC IIa, Alexa Fluor 647 Goat anti-mouse IgG1; Laminin, Alexa Fluor 488 Goat
anti-mouse IgG2a.

Imaging and quantification
Slides were examined using fluorescent microscopy (Nikon Eclipse TE2000-E,
Tokyo, Japan). Within each sample, the largest possible area was imaged (captured at 4x
magnification). Epifluorescence signal was recorded using Texas Red excitation filter
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(534-556 nm) and Cy5 excitation filter (628-672 nm) for MHCI and MHCIIa muscle
fibers, respectively. The FITC excitation filter (450-490 nm) was used to record
epifluorescence signal for laminin. Images were captured in each filter and overlaid using
NIS Elements software (Nikon, Tokyo, Japan). Images were analyzed using Image J
(NIH, Bethesda, MD) after converting post-hoc to 8-bit. Cross-sectional area was
determined by measuring outline of each muscle fiber, determined by laminin-positive
staining; peripheral fibers with irregular staining patterns or disrupted cell membranes
were marked and excluded from analysis.

Statistical analysis
All raw data were log transformed to diminish the effects of nonuniformity.
Dependent t-tests were applied to generate p-values for subsequent analyses described
below. The effects of the training phases on all measurement variables during both CHO
and CP ( NT vs. IT, IT vs. RVT, NT vs. RVT) were analyzed. Likewise, change scores in
the measurement variables during each training phase were compared to determine the
influence of CP compared to CHO (i.e. Δ 30-km TT time NT-IT with CHO vs. Δ 30-km
TT time NT-IT with CP). Statistical analyses were performed using IBM Statistical
Package for Social Sciences (SPSS) 21 for Macintosh (SPSS Inc., Chicago, IL).
The p-values derived from the comparisons outlined above were used to
formulate magnitude-based inferences about the data using methods described by
Hopkins and colleagues (31). A standardized difference in means (mean difference
between treatments divided by the between-subject SD under CHO conditions: SD units)
was calculated for each variable whereby observed values equivalent to or exceeding 0.2
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SD units qualified as a substantial treatment effect (i.e. threshold for substantial effect)
(31). The 0.2 SD unit threshold was used for all variables with the exception of time trial
performance, for which a previously established ‘smallest worthwhile change’ in
performance was used as the threshold (32). The smallest worthwhile change in
performance has been defined as 0.3 x the within subject variability across repeated time
trials, which translates to a ~1% change in performance (0.3 x 3.4%), 0.13 SD units, or
~35 seconds for the current data (32).
A published spreadsheet (33) was used to determine the likelihoods of the true
treatment effect (of the population) reaching the substantial change threshold (0.2 SD);
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% =
unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = almost
certain. If the percent chance of the effect reaching the substantial change threshold was
<25% and the effect was clear, it was classified as a ‘trivial’ effect. If 90% confidence
intervals included values that exceeded the substantial change threshold for both a
positive and negative effect, effects were classified as unclear (>5% chance of reaching
the substantial threshold for both a positive and negative effect). For ease of
interpretation data was displayed as raw means ± SD and/or percent difference between
treatments ± CL (90% confidence limit; to illustrate uncertainty in treatment effects).
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RESULTS
Training Load
Training data throughout NT, IT, and RVT in CP and CHO conditions are
displayed in Figure 3.1. Average daily training volume increased from NT (63 ± 7
min/day) to IT (136 ± 16 min/day) with no significant difference between CP and CHO
conditions (p = 0.401). Average daily training volume decreased from IT (136 ± 16
min/day) to RVT (41 ± 5 min/day) with no significant difference between CP and CHO
conditions (p = 0.380). Average training power decreased from NT (187 ± 28 W) to IT
(170 ± 29 W), with no significant difference between treatment conditions (p = 0.203).
Average training power increased from IT (170 ± 29 W) to RVT (198 ± 37), with no
significant difference between treatment conditions (p = 0.255).

Dietary Intake
Total caloric and macronutrient intake throughout NT, IT, and RVT in CHO and
CP conditions are displayed in Table 3.3. Two subjects were omitted from dietary
analysis due to incomplete dietary records; therefore six subjects are included in the
dietary analysis. Average caloric intake during NT was 3218 ± 735 kcal with the
following carbohydrate (454 ± 150 g), protein (123 ± 23 g), and fat (98 ± 23 g) intake.
Daily caloric and macronutrient intake during IT were similar between CHO (kcal: 3255
± 611 kcal, cho: 471 ± 293 g, pro: 136 ± 27 g, fat: 127 ± 23 g) and CP (kcal: 2609 ± 1443
kcal, cho: 360 ± 106 g, pro: 157 ± 70 g, fat: 123 ± 106 g) conditions. Likewise, daily
caloric and macronutrient intake during RVT were similar between CHO (kcal: 2793 ±
459 kcal, cho: 335 ± 74 g, pro: 117 ± 16 g, fat: 104 ± 21 g) and CP (kcal: 2584 ± 497
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kcal, cho: 344 ± 142 g, pro: 116 ± 16 g, fat: 96 ± 14 g) conditions. The caloric and
macronutrient data do not include treatment beverages.

30-km Time Trial Performance
Time trial performance after NT, IT, and RVT in CP and CHO conditions are
displayed in Figure 3.2. The impact of IT with both CHO and CP on 30-km TT time was
‘unclear’. Relative to IT, RVT ‘likely’ improved TT time with CHO (-114 ± 180 sec) and
‘possibly’ improved TT time with CP (-78 ± 132 sec). Relative to NT, RVT resulted in an
‘unclear’ improvement in TT time with CHO and a ‘very likely trivial’ improvement in
TT performance with CP. Overall, the effects of the nutritional treatments on changes in
performance were ‘unclear’.

Whole Muscle Function
Assessment of whole muscle function was conducted at two different assessment
speeds, 120 deg·sec-1 and 240 deg·sec-1. Peak isokinetic torque of the knee flexors and
extensors at both assessment speeds is displayed in Table 3.4.
120 deg·sec-1
IT ‘likely’ reduced peak isokinetic torque of the knee extensors at 120 deg·sec-1
with CHO (-11.4 ± 14.7 ft·lbs-1) whereas IT had a ‘possibly trivial’ effect on peak torque
with CP (2.3 ± 10.9 ft·lbs-1). Overall CP ‘likely’ preserved peak knee extensor strength
compared to CHO.
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The influence of IT on peak knee flexor torque with CHO was ‘likely trivial’ (-0.8 ± 5.6
ft·lbs-1), while IT ‘possibly’ increased peak knee flexor torque with CP (2.8 ± 4.1 ft·lbs1

). CP ‘likely’ preserved peak knee flexor strength from NT to IT compared to CHO.
RVT had an ‘unclear’ effect on leg extension torque with both CHO and CP,

resulting in an ‘unclear’ treatment effect. The effect of RVT on leg flexion was ‘likely
trivial’ with CHO and ‘possibly trivial’ with CP. Overall there was an ‘unclear’ treatment
effect on knee flexion with RVT.
Comparing NT to RVT, there was a ‘possibly trivial’ reduction in leg flexion
torque with CHO (-2.1 ± 7.8 ft·lbs-1) and a ‘possible’ increase in leg extension torque
with CP (4.7 ± 7.4 ft·lbs-1). However, the treatment effect was ‘unclear’.

240 deg·sec-1
IT ‘likely’ impaired peak knee extension torque at 240 deg·sec-1 with CHO (-9.5
± 16.7 ft·lbs-1) but had a ‘possibly trivial’ effect with CP (-4.1 ± 13.0 ft·lbs-1). Overall
there was an ‘unclear’ treatment effect. IT ‘possibly’ improved peak knee flexion torque
with CHO (2.8 ± 6.4 ft·lbs-1) and ‘likely’ improved knee flexion torque with CP (5.6 ±
5.7 ft·lbs-1), resulting in a ‘likely’ benefit of CP vs. CHO.
RVT had an ‘unclear’ effect on knee extension strength with CHO and a ‘likely
trivial’ effect with CP, resulting in an ‘unclear’ treatment effect.
RVT had a ‘possibly trivial’ effect on peak knee flexion strength with both CHO
and CP, with an ‘unclear’ difference between treatments. Comparing NT to RVT, there
was an ‘unclear’ change in knee extension torque with CHO and a ‘possibly trivial’ effect
with CP, resulting in an ‘unclear’ difference between treatments.
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Comparing NT to RVT, leg flexor torque was ‘likely’ improved with CHO (5.2 ±
8.6 ft·lbs-1) and ‘possibly’ improved with CP (3.8 ± 5.4 ft·lbs-1). However, there was an
‘unclear’ treatment effect.

Muscle Soreness
Muscle soreness ratings throughout NT, IT, and RVT in CP and CHO conditions
are displayed in Figure 3.3. With CHO, IT ‘likely’ increased ratings of muscle soreness
(18.6 ± 28.6 mm), while with CP, IT ‘very likely’ increased rating of muscle soreness
(17.9 ± 16.9 mm). Overall, there was an ‘unclear’ treatment effect.
RVT ‘very likely’ reduced muscle soreness with CHO (-21.7 ± 23.0 mm) and
‘almost certainly’ reduced soreness with CP (-21.4 ± 10.8 mm). There was an ‘unclear’
treatment effect.
Comparing RVT to NT, there was an ‘unclear’ change in muscle soreness, along
with an ‘unclear’ treatment effect.

Serum CK and Cortisol
IT ‘possibly’ reduced CK levels with CHO (-15.6 ± 34.8 U·L-1), but had a ‘likely
trivial’ effect with CP (3.9 ± 23.8 U·L-1). Overall, CK ‘likely’ increase from NT to IT
with CP compared to CHO.
The effect of RVT on CK was ‘unclear’ with both treatments. Consequently, there
was an ‘unclear’ treatment effect.
Compared to NT, RVT had an ‘unclear’ effect on CK with both treatments,
thereby leading to an ‘unclear’ treatment effect.
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IT had an ‘unclear’ effect on cortisol with CHO (-6.2 ± 37.1 mmol·l-1) but
‘possibly’ reduced cortisol with CP (-12.4 ± 26.1 mmol·l-1). Overall, there was an
‘unclear’ difference between treatments.
Changes in cortisol from IT to RVT and from NT to RVT were ‘unclear’ with
CHO and CP, resulting in ‘unclear’ treatment effects.

Whole Muscle Size
Changes in whole muscle size are displayed in Table 3.5. The change in whole
muscle size was ‘unclear’ following IT with both CHO and CP, yet CP ‘possibly’
maintained muscle size compared to CHO (CP: 0.05 ± 0.24 cm, CHO: -0.05 ± 0.38).
RVT had an ‘unclear’ effect on muscle size with CHO and a ‘possibly trivial’ effect with
CP. Therefore, changes in whole muscle size from IT to RVT were ‘possibly’ reduced
with CP compared to CHO (CP: 0.06 ± 0.21, CHO: 0.15 ± 0.36).
Comparing RVT to NT, whole muscle size ‘likely’ increased with CHO (0.18 ±
.28 cm), with an ‘unclear change’ with CP (0.11 ± .31 cm). Overall, there an ‘unclear’
treatment effect on whole muscle size.

Muscle Fiber Cross Sectional Area
Two subjects were omitted from these analyses. One subject was omitted from
analysis on account of impaired tissue samples from biopsies, whereas the other was
omitted from all RVT analysis due to an insufficient tissue yield during the biopsy
procedure.
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IT had an ‘unclear’ impact on MHC I CSA with both treatments, resulting in an
‘unclear’ treatment effect. MHC IIa CSA ‘likely’ increased following IT with CHO
(474.97 ± 770.46 um2) whereas there was an ‘unclear’ change in MHC IIa CSA with CP.
Therefore, CHO ‘likely’ increased CSA compared to CP.
RVT ‘likely’ decreased MHC I CSA with CHO (-574.64 ± 601.40 um2) but had
an ‘unclear’ effect on CSA with CP, resulting in an ‘unclear’ treatment effect. MHC IIa
CSA ‘very likely’ decreased with CHO (-853.46 ± 570.62 um2) but ‘likely’ increased
(165.05 ± 1822.98 um2) with CP, resulting in a treatment effect that was ‘very likely’.
Compared to NT, MHC I CSA was ‘likely’ smaller after RVT with CHO (432.13
± 510.02 um2) but ‘unclear’ with CP, resulting in an ‘unclear’ treatment effect. MHC IIa
CSA was ‘likely’ smaller after RVT compared to NT with CHO (378.49 ± 751.56 um2)
whereas there was ‘unclear’ difference in CSA with CP. There was an ‘unclear’ treatment
effect. Muscle fiber cross-sectional areas following NT, IT, and RVT in CP and CHO
conditions are displayed in Table 3.5.

Body Weight
The impact of IT on body weight was ‘most likely trivial’. However, CP ‘likely’
maintained body weight better than CHO (CP: 0.3 ± 1.1 kg, CHO: -0.6 ± 0.9 kg).
RVT had a ‘most likely trivial’ influence on body weight. Yet, body weight
following RVT was ‘likely’ decreased with CP compared to CHO (CP: -0.2 ± 0.5 kg,
CHO: 0.5 ± 0.9 kg).
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Compared to NT, there was a ‘most likely trivial’ difference in body weight after
RVT. There was an ‘unclear’ treatment effect. Raw means ± SD are displayed in Table
3.6.
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DISCUSSION
This study was designed to assess the impact of carbohydrate and protein
supplementation (CP) on cycling performance and various skeletal muscle parameters
following a period of intensified cycle training (IT), compared to carbohydrate alone
(CHO). Additionally, we examined the effect of CP supplementation on cycling
performance and skeletal muscle adaptations following a period of reduced volume
training (RVT). Although CP supplementation did not impact the ‘unclear’ changes in
cycling performance that occurred with IT, it positively influenced some aspects of
skeletal muscle function and size, compared to CHO alone. Furthermore, CP did not
impact the ‘unclear’ effect on cycling performance or any skeletal muscle parameters
following RVT. This is the first evidence that during- and post-exercise CP
supplementation can better sustain whole muscle function and size during 10 days of IT.
However, we did not observe any clear evidence that continued CP supplementation
throughout 10 days of RVT enhanced the adaptive response to IT. These findings also
provide initial insight into fiber-type specific responses and adaptations to a period of IT
followed by a period of RVT.
Surprisingly, cycling performance was not clearly impaired following IT,
regardless of treatment- a finding contrary to much of the existing literature (17, 18, 25,
27, 30, 40, 81). IT was immediately followed by RVT, a training strategy reported to
facilitate recovery from IT and to possibly enhance performance compared to pre-IT
levels (40, 52, 55–57). RVT induced only a ‘possibly trivial’ effect on cycling
performance. An explanation for the lack of any performance change with such dramatic
adjustments in training is unclear, especially considering that the duration and intensity of
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IT were well within the range (6-14 days with a 50-100% increase in weekly training
duration) of training overload programs shown to impair performance in prior studies
(25, 27, 30, 40, 81). This may be at least partially related to the marked range of racing
and training backgrounds, thereby contributing to substantive variability in the response
to the different training phases. Although all eight subjects were trained endurance
cyclists (VO2max ≥ 50 ml·kg-1·min-1, ≥ 7 hr cycling/week), three subjects had minimal
competitive racing experience prior the initiation of the study. Additionally, the wide age
range (19 – 42 yrs.) and mixed sex (2 female, 6 male) of the cohort presumably
contributed to increased variability in TT performances.
Independent of cycling background, it is plausible that the subjects’ high dietary
protein intake, (CHO- 1.8 gPRO·kg-1BW·day-1, CP- 2.6 gPRO·kg-1BW·day-1, including
supplementation from the treatments) helped them tolerate the heavy training.
Additionally, this high dietary protein intake may have reduced the physiological stress
from IT that is necessary for a super-compensatory response of RVT. Indeed, daily
protein intake during both conditions exceed the recommended daily intake for endurance
athletes of 1.2 - 1.7 gPRO·kg-1BW·day-1 (75, 77). In a recent study (81), cyclists better
sustained cycling performance after 7 days of IT with 3.0 gPRO·kg-1BW·day-1 compared
to a control diet of 1.5 gPRO·kg-1BW·day-1. These findings in combination with the
current study suggest that dietary protein levels near/above the upper limit of the current
recommendations are appropriate for endurance athletes during heavy training.

In

addition to high dietary protein intake, subjects’ daily CHO intake may have contributed
to the unclear effect of CP supplementation. Average CHO intake during both treatments
(CHO - 7.7 g·kg-1BW·day-1, CP - 7.0 g·kg-1BW·day-1) failed to meet current
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recommendations for heavy endurance training (< 8-10 g·kg-1BW·day-1) (15, 16, 59, 69).
As discussed above, Witard et al. (81) reported that high levels of dietary protein intake
attenuates the detrimental effects of IT on cycling performance; there subjects consumed
6.0 gCHO·kg-1BW·day-1, an average intake nearly 1.5 gCHO·kg-1BW·day-1 less than the
current study. Therefore it is possible that the positive effect of protein observed by
Witard (81) were due to the comparatively low CHO availability of their subjects. Also
worth mentioning, is the caloric difference during IT between the CHO and CP
conditions (CHO: 3255 ± 611 kcal; CP: 2609 ± 1443 kcal). Although statistically similar,
the comparatively reduced caloric intake during IT with CP (which was almost
exclusively due to lower carbohydrate intake) may have blunted any difference in
treatment.
Though cycling performance was not influenced by training or treatment, there
was evidence of changes in skeletal muscle function. At 120 deg·sec-1, CP ‘likely’
enhanced whole muscle function of both the knee flexors and extensors following IT,
compared to CHO. CP also ‘likely’ amplified the increase in function of the knee flexors
at 240 deg·sec-1, while knee extensor strength decreased regardless of treatment. The
more apparent benefit of CP on whole muscle function is shown at the slower contractile
velocity. The slower rotational velocity elicits comparatively higher torque values than
the faster assessment speed, and therefore could be a more sensitive measure of peak
muscle function. This notion is supported by the findings of Coutts et al. (17) who
observed clear effects of IT on peak isokinetic torque at 1.05 rad·sec-1, while no clear
effect existed at 5.25 rad·sec-1. Only one other study (71) has assessed the influence of
CP on whole muscle function following IT, reporting a benefit of CP compared to CHO,
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similar to the current findings. To our knowledge, no other study has observed the
changes in whole muscle function throughout a period of IT, followed by a period of
RVT. Although the influence of training on these assessments of whole muscle function
was mixed, CP seemed to preserve several indices of muscle function throughout IT.
However, the practical applications of these changes in muscle function are not apparent,
as they did not translate to improved cycling performance. This observed disconnect from
cycling performance is somewhat explained by the variable changes in muscle function at
240 deg·sec-1 throughout training, as this angular velocity has been shown to closely
relate to cycling specific velocities (62). Further research is needed to delineate how
changes in peak isokinetic torque translate to cycling specific performance.
Creatine kinase (CK) levels and perceived muscle soreness, together offer
valuable insight into possible mechanisms involved in changes in muscle function with
training and nutrition, as they are generally indicative of muscle damage. Although
ratings of muscle soreness increased as a result of IT, as expected (1, 50, 58, 72), the
unclear effect of CP contradicts previous literature (21, 24, 48, 71). Interestingly, changes
in CK levels following IT did not mirror those of perceived muscle soreness. CHO
‘likely’ reduced CK levels during IT compared to CP, although the magnitude of change
in CK was functionally negligible. Accordingly, RVT resulted in no clear effect on the
negligible changes in CK levels with either treatment. The ‘unclear’ influence of CP on
CK response opposes earlier findings of CP attenuating CK levels after heavy training
(48, 63, 71). Given that IT induced no clear effect on cycling performance, and mixed
results with whole muscle function, it is possible that the increased muscle soreness
following IT was a function of psychological stress, rather than cellular
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damage/inflammation. This notion is supported by the lack of clear increases in CK
levels following IT and recent evidence displaying a worsened psychological state
following IT in a similar training model (81).
To further explain the influence of training and nutrition on skeletal muscle
function we examined changes in whole muscle size. To our knowledge, we are the first
to examine whole muscle size and fiber size throughout a block of IT followed by RVT.
Likewise, the influence of CP supplementation on this response is also original. Whole
muscle size was ‘possibly’ better maintained with CP throughout IT, while no clear
treatment effect persisted through RVT. Changes in MHC I CSA were unclear
throughout IT and RVT, agreeing with negligible changes observed in previous studies
(20, 43, 78). Contrary to existing literature demonstrating MHC IIa vulnerability to heavy
training (20, 28, 43), we observed a ‘likely’ increase in CSA among MHC IIa fibers with
CHO, while CP had no clear influence. Following RVT, CHO had the opposite effect,
reducing MHC IIa CSA while CP ‘likely’ increased MHC IIa fiber size. However, MHC
IIa fiber size was no different from NT under either treatment. Given the physiological
variables measured in the current study, it is difficult to expose the mechanisms behind
the independent effects of CP on whole muscle size, together with the influence of CHO
on fiber size. The overall change in whole muscle size observed with CP may be due to
changes other than fiber size, including systemic inflammation and fluid dynamics. The
unclear influence of CP on muscle fiber size throughout IT and RVT is novel, and
mirrors the responses in cycling performance. Changes in muscle function and thus
cycling performance are dependent not only on structural changes, but metabolic and
neurological changes as well.
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The current findings provide preliminary evidence for the potential of during- and
post-exercise CP supplementation throughout IT followed by RVT. During a period of
IT, CP may better sustain skeletal muscle function and whole muscle size compared to
CHO. However, it is important to emphasize that endurance performance, markers of
muscle damage, and muscle fiber size were all minimally effected by CP
supplementation, perhaps as a result of the relatively high dietary protein intake under
both treatment conditions (CHO- 1.8 gPRO·kg-1BW·day-1, CP- 2.6 gPRO·kg-1BW·day-1).
Future research should be conducted to determine if the timing of CP supplementation is
of greater importance for athletes consuming lower quantities of dietary carbohydrate and
protein.
Our inability to delineate any effect of training or CP within the current
experimental model may have arisen from the inclusion both male and female cyclists
with a wide range of competitive cycling experience, thus leading to further variance in
any performance outcomes. Across all subjects, dietary protein intake was relatively high,
which possibly attenuated any measureable difference between treatments. Overall, it is
not clear if CP is effective in improving tolerance to intensified training. Nor is it clear
that CP supplementation can augment the adaptive response to IT, following a period of
reduced training. A moderate-CHO, high-PRO diet appears sufficient to tolerate a block
of intense endurance training, in comparison to when supplemental protein is provided.
Future research is needed to elucidate the underlying mechanisms behind the acute
benefit of CP and whether this is an effective strategy to promote adaptations to longer
durations of heavy training.

63#

#

64

Table 3.1: Subject Characteristics
Subjects, n
8

Age, yr
24.9 ± 7.3

Height, cm
174.8 ± 11.1

Weight, kg
71.8 ± 11.5

VO2max, ml·kg-1·min-1
63.4 ± 7.9

Wmax, Watts
344 ± 53
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Table 3.2: Macronutrient Content of Nutritional Treatments
During Exercise
CHO
CP
Post Exercise
CHO
CP
CHO = carbohydrate; CP = carbohydrate-protein.

CHO

PRO

45 g·hr-1
45 g·hr-1

0 g·hr-1
15 g·hr-1

1.2 g·kg BW-1
1.2 g·kg BW-1

0 g·kg BW-1
0.4 g·kg BW-1
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Table 3.3: Average Daily Dietary Intake
CHO
CP
IT
RVT
IT
RVT
Energy (kcal)
3218 ± 735
3255 ± 611
2793 ± 459
2609 ± 1443
2584 ± 497
Carbohydrate (g)
454 ± 150
471 ± 293
335 ± 74
360 ± 106
344 ± 142
Pro (g)
123 ± 23
136 ± 27
117 ± 16
157 ± 70
116 ± 16
Fat (g)
98 ± 23
127 ± 23
104 ± 21
123 ± 106
96 ± 14
CHO = carbohydrate; CP = carbohydrate-protein. Values are expressed as mean ± SD, not including nutrients from treatment
beverages.
NT
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Table 3.4: Peak Isokinetic Torque

-1

NT

CHO
IT

RVT

NT

120 deg·sec
Knee Extension (ft·lbs-1)
112.3 ± 28.1
100.9 ± 21.5 100.2 ± 30.0
98.6 ± 25.1
-1
Knee Flexion (ft·lbs )
72.7 ± 16.0
71.8 ± 15.8
70.6 ± 16.6
71.2 ± 14.4
240 deg·sec-1
Knee Extension (ft·lbs-1)
80.1 ± 24.0
70.6 ± 18.5
76.5 ± 27.5
75.1 ± 21.6
-1
Knee Flexion (ft·lbs )
54.6 ± 12.9
57.3 ± 12.8
59.8 ± 15.9
55.8 ± 14.0
CHO = carbohydrate; CP = carbohydrate-protein. Values are expressed as mean ± SD.

CP
IT

RVT

100.8 ± 21.8
74.0 ± 15.2

98.4 ± 20.0
75.8 ± 15.5

71.0 ± 11.3
61.5 ± 14.4

71.6 ± 16.7
59.7 ± 13.7
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Table 3.5: Whole Muscle Size and Muscle Fiber Size
CHO
NT
IT
VL Thickness (cm) 2.79 ± 0.45
2.74 ± 0.34
MHC I (um2)
4394 ± 1174
4536 ± 1172
MHC IIa (um2)
4250 ± 851
4725 ± 990

RVT
2.93 ± 0.53
3961 ± 997
3871 ± 766

NT
2.82 ± 0.51
4065 ± 1617
4504 ± 1925

CP
IT
2.89 ± 0.53
3965 ± 1319
4070 ± 1508

RVT
2.98 ± 0.63
4348 ± 1319
4940 ± 1851

Δ VL Thickness
-1.8
5.0
2.5
5.7
(%)
Δ MHC I (%)
3.2
-9.8
-2.5
7.0
Δ MHC IIa (%)
11.2
-8.9
-9.7
9.7
CHO = carbohydrate; CP = carbohydrate-protein. Values are expressed as mean ± SD, where italics are a percentage change
from NT.
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Table 3.6: Body Weight
CHO
NT
IT
RVT
NT
Body Weight (kg)
72.1 ± 11.5 71.5 ± 11.1 71.9 ± 11.1 72.1 ± 11.3
CHO = carbohydrate; CP = carbohydrate-protein. Values are expressed as mean ± SD.

CP
IT
72.4 ± 11.3

RVT
72.2 ± 11.4
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Figure 2.1: Experimental Design
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Figure 2.2: Study Schematic with Corresponding Data Collection
Intensified Cycling Training
Days

-3

VO2max

-1

1

2

3

4

5

6

7

X

TT
Bx

-2

8

9

10

1

X
X

X

Reduced Volume Training

X

X

2

3

4

5

6

7

8

9

10

+1

X
X

X
X

X

VO2max = VO2max, TT = preloaded time trial, Bx = skeletal muscle biopsy
Note: This design will be repeated twice (Figure 1). Therefore, days -1, -2, and -3 correspond to the final 3 days of normal
training, whereas day +1 corresponds to day 1 of washout or study completion.
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Figure 3.1: A, Average daily training duration during normal (NT), intensified (IT), and reduced volume (RVT) training in
CHO and CP conditions. B, Average daily training power during NT, IT, and RVT in CHO and CP conditions. C, Average
daily training heart rate during NT, IT, and RVT in CHO and CP conditions. CHO = carbohydrate; CP = carbohydrateprotein.. Data are displayed as means ± SD.
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Figure 3.1: A, Average daily training duration during normal (NT), intensified (IT), and reduced volume (RVT) training in
CHO and CP conditions. B, Average daily training power during NT, IT, and RVT in CHO and CP conditions. C, Average
daily training heart rate during NT, IT, and RVT in CHO and CP conditions. CHO = carbohydrate; CP = carbohydrateprotein. Data are displayed as means ± SD.
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Figure 3.1: A, Average daily training duration during normal (NT), intensified (IT), and reduced volume (RVT) training in
CHO and CP conditions. B, Average daily training power during NT, IT, and RVT in CHO and CP conditions. C, Average
daily training heart rate during NT, IT, and RVT in CHO and CP conditions. CHO = carbohydrate; CP = carbohydrateprotein. Data are displayed as means ± SD.
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Figure 3.2: A, 30-km time trial finishing time after normal (NT), intensified (IT), and reduced volume (RVT) training in
carbohydrate (CHO) and carbohydrate+protein (CP) conditions. B, 30-km time trial power after NT, IT, and RVT in CHO and
CP conditions. Data are displayed as means ± SD.
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Figure 3.3: Rating of perceived muscle soreness following normal (NT), intensified (IT), and reduced volume (RVT) training.
CHO = carbohydrate; CP = carbohydrate-protein. Data are displayed as means ± SD.
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